Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight

The oligonucleotides clinical trial landscape is expanding rapidly with 200+ companies developing 600+ pipeline drugs. Major players like Novartis, Alnylam Pharmaceuticals, Amgen, and WaVe Life Sciences are advancing promising therapies across various clinical stages. Approximately 20+ oligonucleotides are in late-stage development while 150+ are in mid and early stages. Recent developments include SanegeneBio's $110M Series B funding, FDA approvals for multiple orphan drug designations, and several companies advancing Phase II and Phase III trials.

05/14/2026, 1:00 PM • GlobeNewswire

Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path

Wave Life Sciences regained full rights to WVE-006 from GSK for treating alpha-1 antitrypsin deficiency (AATD), a rare genetic disorder. Wave plans to accelerate the registrational strategy and pursue an accelerated FDA approval pathway, with regulatory feedback expected mid-2026. Clinical trial data from the RestorAATion-2 trial is on track for Q1 2026. WVE stock rose 4.48% on the announcement.

02/02/2026, 2:16 PM • Benzinga

Golden Cross Alert: 3 Stocks With Major Upside Potential

The article highlights three stocks showing potential for upside momentum in 2026 based on golden cross technical signals and fundamental analysis: Sun Communities, Darling Ingredients, and Wave Life Sciences.

12/11/2025, 2:01 AM • Investing

Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Wave Life Sciences announced a public offering of 15,789,475 ordinary shares and pre-funded warrants, expecting to raise approximately $350 million to support its RNA medicines platform and clinical programs.

12/09/2025, 9:50 PM • GlobeNewswire

Why Wave Life Sciences Stock Crushed it Again Today

Wave Life Sciences experienced a significant stock surge following positive Phase 1 clinical study results for its obesity drug candidate WVE-007, with analysts upgrading price targets and recommendations.

12/09/2025, 7:19 PM • The Motley Fool

Why Wave Life Sciences Stock Vaulted 146% Higher on Monday

Wave Life Sciences saw a massive stock surge after reporting promising phase 1 clinical trial results for its investigational weight loss drug WVE-007, which demonstrated significant body fat reduction and potential competitive advantages over existing GLP-1 drugs.

12/08/2025, 6:30 PM • The Motley Fool

Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025

Wave Life Sciences presented preclinical data for WVE-007, a novel RNA medicine targeting obesity by silencing INHBE mRNA. Preclinical studies showed potential for fat loss while preserving muscle mass, with promising initial clinical trial results demonstrating significant Activin E reduction.

11/04/2025, 8:30 PM • GlobeNewswire

Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Wave Life Sciences reported significant Activin E reductions of up to 85% in its INLIGHT clinical trial for obesity treatment, with WVE-007 showing promising results in fat loss potential and safety profile across multiple dose cohorts.

10/29/2025, 10:50 PM • GlobeNewswire

Wave (WVE) Q2 Revenue Drops 56%

Wave Life Sciences reported a challenging Q2 2025, with revenue declining 55.8% to $8.7 million and a net loss of $50.5 million. Despite financial setbacks, the company continues to advance its RNA-based medicine pipeline across multiple therapeutic areas.

07/31/2025, 3:10 AM • The Motley Fool